Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in combination with ...

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a ...

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

Treating initially unresectable gastric or GEJ cancer with camrelizumab plus nab-POF led to an R0 resection rate of 75% in a phase 2 trial.

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...